Canada markets closed

Brooklyn ImmunoTherapeutics, Inc. (BTX)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
9.15+0.03 (+0.33%)
At close: 4:00PM EDT
9.17 +0.02 (+0.22%)
After hours: 07:55PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close9.12
Open9.45
Bid9.14 x 2200
Ask9.24 x 1000
Day's Range9.04 - 9.40
52 Week Range3.50 - 80.67
Volume419,377
Avg. Volume916,284
Market Cap473.326M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
  • GlobeNewswire

    Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq

    Ticker Symbol to Remain “BTX”NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced it will transfer its common stock listing from the NYSE American to the Nasdaq Global Market, effective upon the market close on October 22, 2021. Brooklyn’

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Reports Inducement Grants

    NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced that on September 20, 2021, Roger Sidhu was granted a non-qualified stock option covering 161,300 shares of Brooklyn’s common stock (the “Time-Based Option”) and a restricted stock uni

  • GlobeNewswire

    Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer

    NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases, today announced the appointment of Roger Sidhu, M.D. as its Chief Medical Officer, effective September 20, 2021. “Roger’s extensive R&D experience, including many years in late-stage clinical developm